Updates to the n-3 polyunsaturated fatty acid biosynthesis pathway: DHA synthesis rates, tetracosahexaenoic acid and (minimal) retroconversion.

Docosahexaenoic acid Metabolism Omega-3 Polyunsaturated fatty acid Retroconversion Tetracosahexaenoic acid

Journal

Progress in lipid research
ISSN: 1873-2194
Titre abrégé: Prog Lipid Res
Pays: England
ID NLM: 7900832

Informations de publication

Date de publication:
10 2019
Historique:
received: 25 06 2019
revised: 26 09 2019
accepted: 02 10 2019
pubmed: 19 10 2019
medline: 6 5 2020
entrez: 19 10 2019
Statut: ppublish

Résumé

N-3 polyunsaturated fatty acids (PUFA) and the numerous families of lipid mediators derived from them collectively regulate numerous biological processes. The mechanisms by which n-3 PUFA regulate biological processes begins with an understanding of the n-3 biosynthetic pathway that starts with alpha-linolenic acid (18:3n-3) and is commonly thought to end with the production of docosahexaenoic acid (DHA, 22:6n-3). However, our understanding of this pathway is not as complete as previously believed. In the current review we provide a background of the evidence supporting the pathway as currently understood and provide updates from recent studies challenging three central dogma of n-3 PUFA metabolism. By building on nearly three decades of research primarily in cell culture and oral dosing studies, recent evidence presented focuses on in vivo kinetic modelling and compound-specific isotope abundance studies in rodents and humans that have been instrumental in expanding our knowledge of the pathway. Specifically, we highlight three main updates to the n-3 PUFA biosynthesis pathway: (1) DHA synthesis rates cannot be as low as previously believed, (2) DHA is both a product and a precursor to tetracosahexaenoic acid (24:6n-3) and (3) increases in EPA in response to DHA supplementation are not the result of increased retroconversion.

Identifiants

pubmed: 31626820
pii: S0163-7827(19)30051-7
doi: 10.1016/j.plipres.2019.101008
pii:
doi:

Substances chimiques

Fatty Acids, Omega-3 0
Docosahexaenoic Acids 25167-62-8
tetracosahexaenoic acid 81247-23-6
DNA 9007-49-2

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

101008

Subventions

Organisme : CIHR
Pays : Canada

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Adam H Metherel (AH)

Department of Nutritional Sciences, University of Toronto, Toronto, ON M5S 1A8, Canada. Electronic address: adam.metherel@utoronto.ca.

Richard P Bazinet (RP)

Department of Nutritional Sciences, University of Toronto, Toronto, ON M5S 1A8, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH